Elevated serum ferritin is associated with increased mortality risk in patients with malignant tumorsHigh Serum Ferritin Levels Linked to Higher Mortality Risk

Frontiers in Medicine Published August 5, 2026 DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that elevated serum ferritin is associated with increased mortality risk in patients with malignant tumors.

This meta-analysis analyzed data from 3,083 adult patients with malignant tumors to evaluate the association between serum ferritin (SF) levels and overall survival (OS). The study found that elevated SF is significantly associated with an increased mortality risk, reporting a hazard ratio of 1.78 (95% CI: 1.55-2.05, P < 0.05). When adjusted for publication bias, the hazard ratio for elevated SF remained high at 1.70.

An exploratory analysis for risk stratification identified a range of 300 to 500 ng/mL as a threshold for higher risk of adverse outcomes (hazard ratio 2.26). These findings suggest that serum ferritin may serve as a potential biomarker for identifying high-risk patients within the malignant tumor population.

Several limitations were noted, including the preliminary nature of the reference for risk stratification and the need to verify specific ferritin concentration cut-offs. Additionally, the predictive values of pre-treatment and post-treatment testing are not yet established. Due to these uncertainties, the authors do not recommend routine clinical application at this time, suggesting that larger prospective trials are necessary to confirm these associations.

How this fits prior evidence

This meta-analysis provides a new association between serum ferritin levels and mortality risk in patients with malignant tumors. While it does not directly relate to previously covered topics such as T cell signaling, microbial metabolites, or cGAS–STING activation, it addresses the broader clinical landscape of identifying biomarkers for malignancy progression.

Researchers looked at data from 3,083 adults with malignant tumors and blood cancers. They specifically examined the link between serum ferritin (SF) levels and overall survival rates. The study found that patients with elevated SF levels had a significantly higher risk of mortality compared to those with lower levels.

A specific range of 300 to 500 ng/mL was identified as a high-risk zone for poor outcomes. However, the researchers noted that this finding is preliminary and serves only as a starting point for understanding risk. They also mentioned that more research is needed to confirm exactly where the cutoff point should be.

Because these results are from an observational analysis, they show a link rather than a direct cause. Doctors cannot yet use these findings for routine clinical decisions. More large-scale trials are necessary to determine how these levels can best help predict patient outcomes in everyday practice.

What this means for you:

High serum ferritin is linked to higher mortality risk in some cancers, but more research is needed for clinical use.

Common questions

What specific ferritin level is considered high risk?

An exploratory analysis identified a range of 300 to 500 ng/mL as a high-risk zone for adverse outcomes. However, researchers note that this measurement is currently only a preliminary reference and needs more verification before it can be used in routine clinical practice.

Can doctors use these results to treat patients right now?

Not yet. Because the evidence is preliminary and comes from an analysis of existing data, researchers cannot recommend using these specific ferritin levels for routine clinical decisions at this time. Larger prospective trials are needed to confirm how these findings can help patients.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedAug 2026

View Original Abstract ↓

PurposeSerum ferritin (SF) is a routine biomarker reflecting iron status and systemic inflammation. We performed a systematic review and meta-analysis to validate the prognostic value of circulating SF for overall survival (OS) in adult patients with malignant tumors.Experimental designWe searched PubMed, Embase, Cochrane Library, the Chinese databases CNKI and Wanfang from inception to December 31, 2025, for retrospective cohort studies reporting the association between SF levels and overall survival (OS) in cancer patients. Two reviewers independently screened studies, extracted data, and assessed quality via the Newcastle-Ottawa Scale (NOS). Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated, with prespecified subgroup, sensitivity, and publication bias analyses. This study was prospectively registered in PROSPERO (CRD420251271950).ResultsTen moderate-to-high quality studies (3,083 patients) were included. Elevated SF was significantly associated with increased mortality risk (pooled HR = 1.78, 95% CI: 1.55–2.05, P 0.05). We preliminarily identified a 300–500 ng/mL SF threshold as the high-risk range for adverse outcomes (exploratory analysis, 2 studies, HR = 2.26). Publication bias adjustment did not alter the core conclusion (adjusted HR = 1.70).ConclusionHigher SF correlates with worse OS in adult patients with both hematologic malignancies and solid tumors. Our data only offers preliminary reference for risk stratification, and we cannot recommend routine clinical application right now. Larger prospective trials are needed to verify the ferritin concentration cut-off and different predictive values of pre- and post-treatment testing.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251271950.

Elevated serum ferritin is associated with increased mortality risk in patients with malignant tumorsHigh Serum Ferritin Levels Linked to Higher Mortality Risk

How this fits prior evidence

Common questions

Study Details

Evaluating Exercise Modalities to Improve Sleep Quality in Breast Cancer Survivors

Exercise types linked to better sleep for breast cancer survivors

Clinical research that matters. Delivered to your inbox.

Elevated serum ferritin is associated with increased mortality risk in patients with malignant tumorsHigh Serum Ferritin Levels Linked to Higher Mortality Risk

How this fits prior evidence

Common questions

More on tumor

Study Details

Evaluating Exercise Modalities to Improve Sleep Quality in Breast Cancer Survivors

Exercise types linked to better sleep for breast cancer survivors

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties